Haifeng Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Haifeng Sun has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Bin Xue
Translational Medicine Research Center, Children’s Hospital of Nanjing Medical University
1 shared publication - Chaojun Li
Institute for Brain Tumours, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China
1 shared publication Jianbo Yang
Department of General Surgery, Jinling Hospital, Medical School of Nanjing University, Nanjing, China
1 shared publicationJieshou Li
Department of General Surgery, Jinling Hospital, Medical School of Nanjing University, Nanjing, China
1 shared publication- Li Zhang
Department of General Surgery, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China
1 shared publication - Peng Wang
Department of General Surgery, Jinling Hospital, Medical School of Nanjing University, Nanjing, China
1 shared publication
Latest Publications
- Top Cited Papers
- 13 February 2023
- Published by Springer Nature in Nature Metabolism
- Vol. 5 (2) , 331-348
Total parenteral nutrition impairs glucose metabolism by modifying the gut microbiome
Total parenteral nutrition (TPN) can lead to complications, such as glucose metabolism disorders. While TPN is associated with impairments in intestinal function, the gut barrier and mucosal immunity, the relationship between the gut microbiome and TPN-related glucose metabolism disorders remains to be explored. In a cohort of 256 participants with type 2 intestinal failure, we show that parenteral nutrition providing >80% of total energy induces insulin resistance and a higher risk of complications. Using various male mouse models, we demonstrate that changes in Lactobacillaceae and indole-3-acetic acid (IAA) levels underlie these complications. Lactobacillaceae and IAA levels decrease in TPN-treated mice and participants, while their abundances in the latter are negatively correlated with insulin resistance and serum lipopolysaccharide levels. Furthermore, IAA activates the aryl hydrocarbon receptor and increases glucagon-like peptide-1 secretion through upregulation of Gcg expression and increased stem cell differentiation towards L cells. Finally, liraglutide, a glucagon-like peptide-1 receptor agonist, completely prevents TPN-induced glucose metabolism disorders in mice. Thus, TPN induces glucose metabolism disorders by altering the gut microbiota and its metabolites.
- 13 February 2023
- Published by Springer Nature in Nature Metabolism
- Vol. 5 (2) , 331-348
Top Cited PapersTotal parenteral nutrition impairs glucose metabolism by modifying the gut microbiome
Total parenteral nutrition (TPN) can lead to complications, such as glucose metabolism disorders. While TPN is associated with impairments in intestinal function, the gut barrier and mucosal immunity, the relationship between the gut microbiome and TPN-related glucose metabolism disorders remains to be explored. In a cohort of 256 participants with type 2 intestinal failure, we show that parenteral nutrition providing >80% of total energy induces insulin resistance and a higher risk of complications. Using various male mouse models, we demonstrate that changes in Lactobacillaceae and indole-3-acetic acid (IAA) levels underlie these complications. Lactobacillaceae and IAA levels decrease in TPN-treated mice and participants, while their abundances in the latter are negatively correlated with insulin resistance and serum lipopolysaccharide levels. Furthermore, IAA activates the aryl hydrocarbon receptor and increases glucagon-like peptide-1 secretion through upregulation of Gcg expression and increased stem cell differentiation towards L cells. Finally, liraglutide, a glucagon-like peptide-1 receptor agonist, completely prevents TPN-induced glucose metabolism disorders in mice. Thus, TPN induces glucose metabolism disorders by altering the gut microbiota and its metabolites.